A multicenter, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained-release (SEROQUEL) as monotherapy in the treatment of patients with MDD [major depressive disorder]

Trial Profile

A multicenter, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained-release (SEROQUEL) as monotherapy in the treatment of patients with MDD [major depressive disorder]

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms MOONSTONE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Oct 2011 Results from a prespecified pooled analysis published in the International Clinical Psychopharmacology.
    • 31 Jul 2007 Status changed from in progress to completed
    • 16 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top